Kadimastem, an Israeli biotechnology company, has entered a collaboration with Merck Serono to provide drug screening for multiple sclerosis (MS) and potential other neurodegenerative diseases. Kadimastem will use its platform technology to screen compounds as potential new therapeutics and will receive an initial fee and additional payments based on certain milestones. Financial details were not disclosed.   The drug screening will be performed with cells that Kadimastem produces for its own ce...